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Abstract
Background: The significance of polycystic ovarian morphology and its relation to polycystic
ovary syndrome (PCOS) is unclear, but probably it is associated with higher androgen and insulin
levels and lower sex hormone binding globulin (SHBG) in absence of identifiable differences in
gonadotropin dynamics. The aim of this study was to evaluate ovarian morphology in patients
affected by PCOS with different ovulatory responses to metformin.
Methods: In this cross-sectional analysis, we studied 20 young normal-weight PCOS patients who
had received a six-month course of metformin treatment. Ten of these patients remained
anovulatory (anovulatory group), whereas other ten became ovulatory, but failed to conceive
(ovulatory group). Other ten age- and body mass index (BMI)-matched PCOS subjects were also
enrolled as controls and observed without any treatment (control group).
Results: After six months of metformin, in both PCOS treated groups, a similar improvement in
testosterone (T) and insulin resistance indexes was observed. Moreover, in one (10.0%) and nine
(90.0%) subjects from anovulatory and ovulatory PCOS groups, respectively, ovarian morphology
changed, whereas a significant reduction in ovarian dimension was observed in the PCOS ovulatory
group only.
Conclusion: PCOS patients under metformin administration demonstrate a change in ovarian
morphology closely related to ovulatory response.
Background
Polycystic ovary syndrome (PCOS) was firstly defined by
the presence of oligo/amenorrhea and hyperandrogenism
in association with polycystic ovary (PCO) morphology
seen at the time of surgery [1] and, thereafter, observed by
ultrasound [2]. Moreover, PCO morphology is not
pathognomonic of PCOS because it was also found in
childhood, adolescence [3,4], menopausal women [5,6],
and in patients with clinical evidence of hyperandrogen-
ism in absence of irregular menstrual cycles [7-9].
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combined with other PCOS features is still unclear. How-
ever, few reports from the previous studies [7,10-13] sug-
gested that this finding is often associated to abnormal
gonadotropin levels, lower levels of insulin growth factor-
binding protein-1 (IGF-BP1), increased insulin resistance
and increased ovarian 17-hydroxiprogesterone (17-OHP)
and androgen responses to gonadotropins-releasing hor-
mone (GnRH)-agonists.
Metformin is an insulin sensitizing drug that has been
recently introduced for treating women with PCOS due to
the knowledge that insulin resistance with compensatory
hyperinsulinemia is probably a key factor for the syn-
drome's pathogenesis [14]. The exact mechanism through
metformin acts in PCOS is still unknown. Certainly, met-
formin exerts systemic actions on glucose-insulin metab-
olism regulation [15,16], even if a cause-effect
relationship between its systemic actions and improved
features of PCOS has not been demonstrated yet [16]. In
addition, peripheral effects of metformin, dependent and/
or independent of its insulin-sensitizing action, have been
also found in several experimental studies [16,17]. In par-
ticular, our previous data suggested a specific effect of
metformin on ovaries, showing that PCOS patients ovu-
lating under treatment had an improved ovarian artery
blood flow, and a better dominant follicle and corpus
luteum vascularization [17].
To date, there are no studies investigating the relationship
between functional response to metformin and ovarian
morphological and/or structural changes. Based on these
considerations, the aim of the present study was to evalu-
ate metformin effects on ovarian morphology in patients
with PCOS who had showed a different response to the
treatment.
Methods
The procedures used were in accordance with the guide-
lines of the Helsinki Declaration on Human Experimenta-
tion and the Good Clinical Practice (CGP) guidelines. No
approval by the Institutional Review Board was required
due to the retrospective nature of the study. However, a
written consent was obtained by all patients for their data
processing before beginning the study.
Clinical charts of patients, who referred to our Depart-
ment for PCOS-related disorders within the last five years,
were carefully screened and, among them, 30 young nor-
mal-weight PCOS patients were successively enrolled.
Diagnosis of PCOS was initially based on the presence of
both chronic anovulation and clinical and/or biochemi-
cal hyperandrogenism [18]. All PCOS subjects had origi-
nally bilateral polycystic ovary (PCO), as defined by
previous diagnostic criteria [19].
Twenty PCOS patients had received metformin at the
same regimen (daily two tablets 850 mg each) during the
previous six months. Ten of these subjects remained ano-
vulatory (anovulatory group) despite treatment, whereas
other ten patients became ovulatory but failed to conceive
(ovulatory group). Normal ovulatory status was defined
by plasma progesterone (P) assay [> 10 ng/mL, (SI: 32
nmol/L)] performed seven days before the expected men-
ses and by the presence of regular menstrual bleedings in
three consecutive evaluations.
Other 10 PCOS subjects, who did not receive any treat-
ment and remained anovulatory throughout the follow-
ing six months, were considered as controls (control
group). Ovulatory, anovulatory and control patients were
matched for age and body mass index (BMI, kg/m2).
Exclusion criteria were considered as: age less than 18 or
higher than 35 years, BMI less than 18 or higher than 25,
presence of neoplastic, endocrine, metabolic, hepatic and
cardiovascular disorders or other concurrent medical ill-
nesses, and current or previous (within the last six
months) use of hormonal drugs. In addition, subjects
with previous pelvic surgery and organic pelvic diseases,
and women intentioned to start a diet or a specific pro-
gram of physical activity were excluded.
Biochemical, clinical, and ultrasonographic data, per-
formed at baseline and at six-month follow-up were col-
lected.
A complete hormonal and metabolic pattern was
recorded for each subject. Free androgen index (FAI) [T
(nmol/l)/SHBG × 100], homeostasis model analysis
(HOMA) [fasting glucose (mmol/L) × fasting insulin (U/
mL)/22.5] [20] and the fasting glucose-to-insulin ratio
(GIR) (mg/10-4U) were also calculated.
Anthropometric measurements [including height, weight,
BMI and waist-to-hip ratio (WHR)], Ferriman-Gallwey
score [21], and ultrasonographic data were noted for each
subject. Transvaginal ultrasonographic examinations had
been performed by the same experienced operator (A.F.)
during the early follicular phase (2nd–3rd day) of a sponta-
neous or P-induced bleedings, and ovarian dimension
and morphology were noted bilaterally in each subject. In
particular, ovarian dimensions had been obtained by
measuring the main three diameters and applying the
ellipsoid formula, and ovarian morphology had been
defined as PCO or not PCO according to published crite-
ria [19].
Statistical analysis
The normal distribution of continuous variables was eval-
uated by using the Kolmogrov-Smirnov test, and continu-Page 2 of 5
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(SD). Continuous variables were analyzed with the one-
way analysis of variance (ANOVA) and ANOVA for
repeated measures with Bonferroni test for the post-hoc
analysis.
The Pearson chi-square test was performed for categorical
variables; conversely, the Fisher's exact test was required
for the frequency tables when more than 20% of the
expected values were less than 5.
The present study is a retrospective analysis on few PCOS
patients for each group. Furthermore a post-study power
and the sample size for ovarian morphology change rate
were calculated in order to design a well powered (> 80%)
RCT. The post-study power analysis and the sample size
calculation were performed by the use of SamplePower
release 2.0.
Statistical significance was set at P < 0.05 for all statistical
analyses. The Statistics Package for Social Science (SPSS
14.0.1, 18 Nov 2005; SPSS Inc., Chicago, IL, USA) was
used.
Results and discussion
In our population, both the National Institute of Health
(NIH) and the European Society for Human Reproduc-
tion (ESHRE)/American Society of Reproductive Medicine
(ASRM) [16] for PCOS diagnosis were satisfied.
No difference at baseline was detected in any parameter
evaluated among groups (Table 1). After six months of
treatment, testosterone (T), androstenedione (A), SHBG
and fasting insulin levels, FAI, GIR and HOMA resulted
significantly (P < 0.05) changed from baseline in both
PCOS treated groups (Table 1). At the same time, signifi-
cant (P < 0.05) differences between anovulatory and ovu-
latory PCOS groups were observed in SHBG, fasting
insulin, GIR and HOMA (Table 1). Lastly, the mean vari-
ation between anovulatory and ovulatory PCOS groups
was not different in the clinical, hormonal and metabolic
parameter evaluated (Table 1).
At enrollment, all PCOS patients had bilateral PCO. After
six months of treatment, ovarian morphology changed in
one and nine subjects from anovulatory and ovulatory
PCOS groups, respectively [1/10 (10.0%) vs. 9/10
(90.0%), respectively; P < 0.001], while no change was
observed in the control group. In particular, only two
patients from the ovulatory PCOS group had no PCO
morphology, whereas in the others a unilateral PCO mor-
phology was observed.
At baseline, no significant difference was observed among
groups in ovarian dimensions (13.9 ± 1.1 vs. 13.6 ± 1.0 vs.
13.6 ± 1.0 for anovulatory PCOS, ovulatory PCOS and
controls, respectively) (Figure 1). In addition, no change
from baseline in ovarian dimensions was observed after
six months in the anovulatory PCOS group and in con-
trols (13.4 ± 1.0 vs. 14.2 ± 1.6, respectively), whereas a sig-
Table 1: Clinical, hormonal and metabolic data of PCOS treated patients (anovulatory and ovulatory groups) and PCOS untreated 
controls (control group) at baseline and at six-month follow-up.
Group Anovulatory PCOS (n. 10) Ovulatory PCOS (n.10) Control (n. 10)
Baseline Six months Baseline Six months Baseline Six months
Age (years) 28.20 ± 3.45 28.20 ± 3.42 28.10 ± 3.31 28.10 ± 3.33 28.40 ± 3.43 28.40 ± 3.43
BMI (Kg/m2) 22.92 ± 1.51 23.84 ± 1.46 22.93 ± 1.71 22.81 ± 2.08 22.99 ± 1.71 23.13 ± 1.98
WHR 0.85 ± 0.11 0.83 ± 0.14 0.84 ± 0.13 0.84 ± 0.12 0.86 ± 0.10 0.86 ± 0.16
Ferriman-Gallwey score 12.70 ± 2.41 12.70 ± 2.26 12.13 ± 2.34 11.81 ± 2.48 12.68 ± 2.53 12.54 ± 1.94
FSH (mIU/mL) 5.83 ± 1.40 5.82 ± 1.25 5.78 ± 1.51 5.68 ± 1.52 5.63 ± 1.70 5.62 ± 1.27
LH (mIU/mL) 12.65 ± 3.51 12.14 ± 1.52 11.73 ± 3.64 11.58 ± 3.56 12.90 ± 4.15 12.30 ± 3.00
TSH (U/mL) 3.10 ± 0.73 3.14 ± 0.49 2.97 ± 0.83 2.99 ± 0.62 3.0 ± 0.68 3.00 ± 0.52
PRL (ng/mL) 9.52 ± 1.81 10.02 ± 1.97 9.12 ± 2.31 8.99 ± 2.23 9.89 ± 2.02 10.09 ± 1.32
E2(pg/mL) 48.80 ± 14.95 48.18 ± 14.90 52.28 ± 17.02 53.93 ± 13.39 51.77 ± 9.10 52.55 ± 14.60
P (ng/mL) 1.27 ± 0.45 1.26 ± 0.31 1.39 ± 0.42 1.29 ± 0.62 1.43 ± 0.36 1.46 ± 0.34
17-OHP (g/L) 1.74 ± 0.50 1.59 ± 0.82 1.54 ± 0.53 1.50 ± 0.63 1.84 ± 0.50 1.93 ± 0.71
T (ng/mL) 4.70 ± 1.23 4.55 ± 1.11* 5.01 ± 1.64 3.41 ± 0.98* 5.15 ± 1.58 5.20 ± 0.78
A (ng/mL) 4.59 ± 1.99 4.34 ± 1.80* 5.16 ± 1.74 3.23 ± 1.07^ 4.97 ± 1.36 4.75 ± 0.99
DHEAS (ng/mL) 2690.01 ± 195.67 2653.48 ± 126.05 2685.72 ± 204.65 2557.25 ± 437.86 2511.82 ± 242.16 2483.07 ± 562.54
SHBG (nmol/L) 31.4 ± 1.78 35.90 ± 1.66*° 32.40 ± 3.86 42.82 ± 2.39^ 32.10 ± 2.51 33.64 ± 2.45
FAI (%) 15.06 ± 4.35 14.37 ± 4.15* 14.97 ± 4.39 10.44 ± 3.01^ 13.60 ± 3.39 12.94 ± 3.19
Fasting glucose (mmol/L) 4.72 ± 0.45 4.79 ± 0.33 4.65 ± 0.50 5.03 ± 0.98 4.73 ± 0.38 4.84 ± 0.43
Fasting insulin (U/mL) 16.24 ± 3.60 14.94 ± 2.36*° 15.63 ± 4.94 12.98 ± 1.53* 17.92 ± 4.35 12.27 ± 0.84
GIR (mg/10-4 U) 5.59 ± 1.16 6.53 ± 1.00*° 5.96 ± 1.62 7.38 ± 1.14* 5.32 ± 1.39 5.45 ± 0.92
HOMA 3.32 ± 0.61 3.02 ± 0.46*° 3.10 ± 0.62 2.61 ± 0.39* 3.51 ± 0.66 3.47 ± 0.25
* P < 0.05 vs. baseline; ^ P < 0.001 vs. baseline; ° P < 0.05 vs. ovulatory PCOS group.Page 3 of 5
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group (13.9 ± 1.1 vs. 12.5 ± 2.4; P = 0.035).
Considering that the ovarian morphology changed in
90% and 10% of the ovulatory and anovulatory groups,
respectively, the post-study power analysis showed a
power of > 90% for this study, and very few patients per
group will be required in order to detect the effect of met-
formin on ovarian morphology with a power of 80%.
Our study was aimed to find, if any, a relationship
between the systemic effects on hyperinsulinemia and
insulin resistance due to the administration of a largely
used insulin sensitizing agent, such as metformin, and
modification in ovarian morphological features of PCOS
patients.
In a recent study [13] on patients affected by PCOS
according to the NIH diagnostic criteria, a prevalence of
95% of ovarian dimension and/or structure alterations
was found. In addition, the Pearson's correlation analysis
showed that the single factor closely related to ovarian
volume was the insulin levels, whereas no other signifi-
cant correlation between altered ovarian morphology and
biochemical features of PCOS was observed [13].
On the other hand, a significant higher antral follicles
count (AFC) was observed in insulin resistant PCOS
patients in comparison with not insulin resistant ones,
and a direct relationship between AFC and GIR was suc-
cessively demonstrated [22].
Considering these findings, the present study analyzed the
effects of metformin on ovarian morphology in two pop-
ulations of young normal-weight PCOS patients who ovu-
lated or did not ovulate under treatment.
As expected, systemic effects of metformin on androgen
levels and insulin sensitivity indexes were reported in
both ovulatory and anovulatory PCOS patients under
treatment.
Even if the meaning of ovarian structure remains debated
[23-25], our preliminary results on few patients showed
significant change in both ovarian dimension and mor-
phology only in PCOS women who ovulated under met-
formin. In fact, in 90% of patients who responded to the
treatment were reported ovarian morphologic changes.
Specifically, in only two out of ten patients PCO morphol-
ogy disappeared in both ovaries, whereas in the others a
unilateral PCO morphology was observed.
Similarly, ovarian volume was significantly reduced after
metformin only in patients ovulating after treatment,
whereas no significant change was reported in patients
who remained anovulatory such as in untreated PCOS
controls.
Current results are in agreement with those obtained in a
recent randomized controlled study, in which Romualdi
et al. [27] hypothesized a peripheral effect of metformin
independent to its insulin-sensitizing properties. The
authors [27] showed an improved clinical and biochemi-
cal hyperandrogenism and a reduced ovarian volume and
stromal compartment in normal-weight normoinsuline-
mic PCOS patients after three and six months of met-
formin, without any effect on glucose and insulin
metabolism.
On the other hand, six months of metformin administra-
tion was demonstrated to have beneficial effects on folli-
cle growth in women with PCOS, as demonstrated by
decrease of anti-Müllerian hormone levels, such as of fol-
licle number and ovarian volume [28]. Furthermore, no
hormonal and metabolic data were evaluated after treat-
ment, thus no correlation with ovarian morphologic
changes was feasible to find.
Finally, a significant acute effect of one-week metformin
administration in PCOS patients was observed in AFC,
even if a significant improvement of insulin sensitivity
was detected at the same time [22]. Unfortunately, based
on these considerations, it is still unclear if the changes in
ovarian morphology observed only in patients ovulating
Ovarian dimension (cm3 ± SD) in PCOS patients (anovulatory and ovulatory gr ups) and controls (control group) at base-li e and  six-m th follow-upFigure 1
Ovarian dimension (cm3 ± SD) in PCOS patients 
(anovulatory and ovulatory groups) and controls 
(control group) at baseline and at six-month follow-
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under treatment could be considered as a direct effect of
metformin on the ovary or an epiphenomenon of the
improved hormonal and metabolic pattern. Moreover, it
is unclear, although very likely, if the ovulation itself
could be a pivotal factor in the ovarian morphology
changes. To this regard, further studies evaluating the
intra-ovarian biochemical pattern in patients with differ-
ent clinical response to metformin are guaranteed.
Conclusion
Regardless of its systemic effects on hormonal and/or met-
abolic pattern, metformin administration modifies ovar-
ian morphology in PCOS patients who ovulated under
treatment probably by a direct peripheral action. How-
ever, further well-powered data are needed to completely
explain the exact mechanisms by which metformin exerts
its beneficial effects on the syndrome.
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